Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Qi, Jun
Item TypeName
Academic Article BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.
Concept Xenograft Model Antitumor Assays
Academic Article Targeting MYCN in neuroblastoma by BET bromodomain inhibition.
Academic Article Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.
Academic Article Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
Academic Article Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Academic Article HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist.
Academic Article The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models.
Academic Article Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.
Grant Targeting DOT1L for Degradation in MLL-rearranged Leukemia
Academic Article Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts.
Academic Article Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Academic Article BET bromodomain is a novel regulator of TAZ and its activity.
Grant Transcriptional and Epigenetic Adaptation as Novel Therapeutic Vulnerabilities for Mantle Cell Lymphoma
Search Criteria
  • primary
  • derived
  • xenograft
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.